LtaS-IN-1

Research use only, not for human use.

LtaS-IN-1 is an effective inhibitor of Lipoteichoic acid synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology.

LtaS-IN-1 is an effective inhibitor of Lipoteichoic acid synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 is against Enterococcus spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 inhibits strain E1630 and E1590 with MIC values of 0.5 μg/mL.(In Vitro):LtaS-IN-1 (20 μM) combines with either ampicillin (20 μg/mL), gentamicin (10 μg/mL), linezolid (5 μg/mL), daptomycin (10 μg/mL+50 μg/mL calcium chloride) or vancomycin (20 μg/mL) can inhibit strains E7128 and E7130 growth by 97-100%, while LtaS-IN-1 alone only gives 73% (strain E7128) and 8% (strain E7130) of growth inhibition, respectively. LtaS-IN-1 (0-100 μM) inhibits strain E745 growth as a concentration-dependent manner. LtaS-IN-1 (10 μM) leads to a 60% reduction in the final OD600 for this strain. Meanwhile, LtaS-IN-1 does not affect E. faecium growth in control group.

——

Others

Other Targets

GABA

——

——

877950-01-1

427.4

C24H17N3O5

>98% (HPLC)

——

O=C(COC(=O)Cc1coc2ccc3ccccc3c12)Nc1nnc(o1)-c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years